Köhler P, Baufeld H, Stöckel A, Ziegenhorn A
Z Gesamte Inn Med. 1982 Oct 1;37(19):654-8.
The connection between decreased concentration of HDL-cholesterol in the serum and increased risk of arteriosclerosis has attracted the attention to such sizes of influence which are able to decrease the HDL-cholesterol-concentration. In these cases the question is asked, whether the analytic reliability of the techniques which are at the disposal for the estimation of HDL-cholesterol is sufficient for the recognition of the changes of the concentration to be expected. To the sizes of influence belong medicaments which cannot be fancied away in the therapy of cardiovascular diseases; thus the beta-receptor blockers talinolol and propranolol. The examination of 118 cardiologically treated patients yields the result that there is no particular risk of the patients treated by means of these medicaments, since an essential decrease of the HDL-cholesterol-concentration could not be proved.
血清中高密度脂蛋白胆固醇浓度降低与动脉硬化风险增加之间的关联,已引发人们对能够降低高密度脂蛋白胆固醇浓度的这类影响因素的关注。在这些情况下,人们会提出这样的问题,即用于估算高密度脂蛋白胆固醇的现有技术的分析可靠性,对于识别预期的浓度变化是否足够。影响因素包括在心血管疾病治疗中无法省去的药物;例如β受体阻滞剂他林洛尔和普萘洛尔。对118例接受心脏病治疗的患者进行检查后得出的结果是,使用这些药物治疗的患者不存在特殊风险,因为并未证实高密度脂蛋白胆固醇浓度有显著降低。